GNTA - יחס חוב להיוון בספרים Genenta Science SpA

Genenta Science S.p.A. (GNTA) brings together leading geneticists to create innovative lentiviral brain therapies. Developing methods to combat solid tumors through targeted drug delivery reduces risks. The GURU.Markets service features a line chart of the debt-to-equity ratio, where 0.34 serves as the final level marker. The lack of profit during the testing stage makes the financial position dependent on external partners.

The diversification of the Genenta Science (GNTA) gene-therapy platform across various tumor types minimizes the risks of clinical failures. An analysis of the debt-to-book capitalization ratio allows for an assessment of this strategy's resilience. This metric compares total loans against net assets, identifying financing overheating or inefficient capital utilization. A lower ratio protects the investor from debt traps. This balance sheet confirms the asset's financial viability.